• Minerva Neurosciences published a medical research presentation on roluperidone for negative symptoms of schizophrenia.
• The confirmatory C19 trial is actively enrolling, targeting 380 patients for a 12-week placebo-controlled efficacy evaluation.
• A subsequent 52-week phase will assess safety and relapse against antipsychotics.
• Combined C03 and C07 analyses showed significant improvement in primary negative symptoms versus placebo with roluperidone 64 mg (p=0.031).
• C07’s negative-symptom result was nominally significant; both studies showed statistically significant improvements in personal and social functioning at 64 mg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.